Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate

被引：0
|
作者：
Martin Huliciak
Ivona Lhotska
Hana Kocova-Vlckova
Veronika Halodova
Tomas Dusek
Filip Cecka
Frantisek Staud
Ivan Vokral
Lukas Cerveny
机构：
[1] Charles University,Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove
[2] Charles University,Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Kralove
[3] University Hospital Hradec Kralove,Department of Surgery
来源：
Pharmaceutical Research | 2023年 / 40卷
关键词：
intestinal permeability; P-glycoprotein; sofosbuvir; tenofovir alafenamide fumarate; tenofovir disoproxil fumarate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2109 / 2120
页数：11
相关论文
共 50 条
  • [1] Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate
    Huliciak, Martin
    Lhotska, Ivona
    Kocova-Vlckova, Hana
    Halodova, Veronika
    Dusek, Tomas
    Cecka, Filip
    Staud, Frantisek
    Vokral, Ivan
    Cerveny, Lukas
    [J]. PHARMACEUTICAL RESEARCH, 2023, 40 (09) : 2109 - 2120
  • [2] Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
    De Clercq, Erik
    [J]. BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 1 - 7
  • [3] Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?
    Aloy, Blandine
    Tazi, Imane
    Bagnis, Corinne Isnard
    Gauthier, Marion
    Janus, Nicolas
    Launay-Vacher, Vincent
    Deray, Gilbert
    Tourret, Jerome
    [J]. AIDS REVIEWS, 2016, 18 (04) : 184 - 192
  • [4] A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
    Wassner, Chanie
    Bradley, Nicole
    Lee, Yuman
    [J]. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2020, 19
  • [5] Tenofovir alafenamide versus tenofovir disoproxil fumarate is there a true difference in safety?
    Pepperrell, T.
    Hughes, S.
    Gotham, D.
    Pozniak, A.
    Boffito, M.
    Pilkington, V.
    Hill, A.
    [J]. HIV MEDICINE, 2019, 20 : 92 - 92
  • [6] RENAL AND BONE SAFETY OF TENOFOVIR ALAFENAMIDE VS TENOFOVIR DISOPROXIL FUMARATE
    Post, Frank
    Sax, Paul
    Saag, Michael
    Yin, Michael
    Oka, Shinichi
    Koenig, Ellen
    Trottier, Benoit
    Andrade, Jaime
    Cao, Huyen
    Fordyce, Marshall
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A48 - +
  • [7] Switching tenofovir disoproxil fumarate to tenofovir alafenamide not only bone and kidney
    Berger, F.
    Milinkovic, A.
    Arenas-Pinto, A.
    Mauss, S.
    [J]. ANTIVIRAL THERAPY, 2018, 23 : A48 - A48
  • [8] Switching tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults
    Orkin, C.
    Clarke, A.
    Gallant, J.
    Daar, E.
    Raffi, F.
    Antonucci, S.
    Mingjin, Y.
    Chang, A.
    Rhee, M.
    [J]. HIV MEDICINE, 2016, 17 : 18 - 18
  • [9] Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back
    Milinkovic, Ana
    Berger, Florian
    Arenas-Pinto, Alejandro
    Mauss, Stefan
    [J]. AIDS, 2019, 33 (15) : 2387 - 2391
  • [10] Which Form of Tenofovir Should Be Used Worldwide: Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide?
    Hill, Andrew
    [J]. CLINICAL INFECTIOUS DISEASES, 2024,
12345